1.09

1.80% -0.02

After Hours: 1.09

Artelo Biosciences Inc (ARTL)

Overview News Price History Financials Discussions Forecast Stock Split

Artelo Biosciences Inc stock is traded at $1.09, with a volume of 114.82K. It is down -1.80% in the last 24 hours and down -21.01% over the past month. Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Previous Close:

$1.11

Open:

$1.11

24h Volume:

114.82K

Relative Volume:

0.04

Market Cap:

$3.80M

Revenue:

Net Income/Loss:

$-13.47M

P/E Ratio:

-0.028

EPS:

-38.9215

Net Cash Flow:

$-8.38M

1W Performance:

-0.91%

1M Performance:

-21.01%

6M Performance:

-72.26%

1Y Performance:

-96.38%

1-Day Range:

$1.08

$1.12

1-Week Range:

$1.0401

$1.15

52-Week Range:

$1.03

$85.80

Artelo Biosciences Inc Stock (ARTL) Company Profile

Name

Artelo Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

858-925-7049

Address

505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA

Employee

Twitter

@ArteloBio

Next Earnings Date

2026-08-12

Latest SEC Filings

ARTL's Discussions on Twitter

Compare ARTL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARTL Artelo Biosciences Inc	1.09	3.90M	0	-13.47M	-8.38M	-38.92
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-25	Upgrade	D. Boral Capital	Hold → Buy
Feb-12-21	Initiated	Ladenburg Thalmann	Buy

Artelo Biosciences Inc Stock (ARTL) Latest News

Jul 01, 2026

Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus

Jul 01, 2026

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Yahoo Finance Singapore

Jul 01, 2026

Jun 30, 2026

Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK

Jun 30, 2026

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times

Jun 30, 2026

Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative

Jun 30, 2026

Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models - Stock Titan

Jun 30, 2026

Jun 29, 2026

Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK

Jun 29, 2026

Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com

Jun 29, 2026

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times

Jun 29, 2026

Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada

Jun 29, 2026

Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative

Jun 29, 2026

Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan

Jun 29, 2026

Jun 26, 2026

Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView

Jun 26, 2026

Jun 24, 2026